MBX Biosciences posts ENDO 2026 canvuparatide presentation update

MBX Biosciences, Inc.

MBX Biosciences, Inc.

MBX

0.00
  • MBX Biosciences published an ENDO 2026 presentation highlighting canvuparatide, a once-weekly PTH replacement candidate for chronic hypoparathyroidism.
  • Phase 2 results were described as positive, with Phase 3 initiation targeted for Q3 2026.
  • The presentation framed chronic hypoparathyroidism as affecting more than 250,000 patients across the US and EU.
  • Study design details included a 12-week Phase 2 trial with a 2-year open-label extension tracking responder rates, urine calcium, bone markers, and immunogenicity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.